The choice of the MOIs relies on the evidence that antivirals 5BVdU + IFN-α (which demonstrate greater efficacy when compared to acyclovir) cannot effectively inhibit viral replication at MOIs higher than 0.001 across 7 days following infection (Zheng et al. 2020a). The gene discussed is IFNA1; the disease is infection.